Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma.

Abstract

PURPOSE:

L-type amino acid transporter 1 (LAT1) is linked to tumor cell proliferation, angiogenesis, and survival in various human cancers. Although the expression of LAT1 was identified as a significant prognostic predictor after surgery in patients with pancreatic ductal adenocarcinoma (PDAC), little is known about the clinical significance of LAT1 as a chemotherapeutic resistance factor in PDAC.

METHODS:

A total of 110 patients with surgically resected PDAC were retrospectively reviewed as the training set. Immunohistochemical staining of resected tumor specimens was assessed using anti-LAT1 antibodies. In vitro analysis of chemotherapy resistance and LAT1 function using PDAC cell lines was also performed.

RESULTS:

The rate of high expression of LAT1 was 64.1% (71/110). The high expression of LAT1 protein was significantly associated with tumor differentiation, tumor depth (T factor), lymph node metastasis, venous invasion, recurrence, and clinical response. By multivariate analysis, LAT1 was validated as an independent prognostic factor for predicting worse survival after surgery. We analyzed the TCGA data set and obtained similar results that the survival rates of SLC7A5 high expression group were poorer than that of low expression group. LAT1 could successfully predict the outcome of patients who received adjuvant chemotherapy after surgery (n = 88) and systemic chemotherapy after recurrence (n = 56). All patients with high LAT1 expression were non-responders, whereas approximately 30% of the patients with low LAT1 expression responders (p = 0.0002). By analyzing the TCGA online database, it was found that LAT1 closely correlated with hypoxia-induced genes, such as PTGES, PYGL, and KPNA2.

CONCLUSION:

LAT1 as an independent prognostic marker is a potential molecular targeting gene to reduce chemoresistance and tumor growth in patients with PDAC, supported by our in vitro study.

• Authors: Bolag Altan, Kyoichi Kaira, Akira Watanabe, Norio Kubo, Pinjie Bao, Gantumur Dolgormaa, Erkhem-Ochir Bilguun, Kenichiro Araki, Yoshikatsu Kanai, Takehiko Yokobori, Tetsunari Oyama, Masahiko Nishiyama, Hiroyuki Kuwano, Ken Shirabe
• Journal: Cancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 81 Issue 1 Pg. 141-153 (01 2018) ISSN: 1432-0843 [Electronic] Germany
• PMID: 29149426 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Large Neutral Amino Acid-Transporter 1

Topics

• Aged
• Antineoplastic Agents (therapeutic use)
• Carcinoma, Pancreatic Ductal (drug therapy, metabolism, pathology)
• Cell Line, Tumor
• Drug Resistance, Neoplasm (genetics)
• Female
• Humans
• Immunohistochemistry
• Kaplan-Meier Estimate
• Large Neutral Amino Acid-Transporter 1 (genetics, metabolism)
• Male
• Middle Aged
• Pancreatic Neoplasms (drug therapy, metabolism, pathology)
• Prognosis
• Retrospective Studies
• Up-Regulation